New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
VHH Antibody Repertoire to Phage Library Comparison
Project Summary Camelids such as llamas and alpacas produce conventional antibodies as well as heavy-chain only antibodies (HCAbs) from which the small, stable antigen-binding domain (VHH) can be extracted. Abterra Biosciences developed Reptor, a proprietary antibody...
Case Study: Reptor Biological vs Technical Replicates
Project Summary Next-generation sequencing of B cell populations (Rep-Seq) has become a powerful tool in immunology and antibody discovery. At Abterra Bio we developed Reptor, an integrated Rep-Seq sequencing and analysis service. A key goal of Reptor is to provide...
Abterra Opens Its Doors To Celebrate New Location With Open House
Celebrating milestones is an important part of our personal and professional journeys. We wanted to commemorate this exciting new chapter in Abterra's story with the people who mean the most to us: our devoted employees, cherished families, esteemed investors, and...
Get In Touch